RediCare’s Clinical Outcomes to be Presented at the European Society of Cardiology Congress in September.
Aug 2021 -- RediCare’s summary clinical outcomes from its Control Digital Therapeutic over the last 5 years have been accepted to be presented at the European Society of Cardiology congress meeting in Sept. This is further recognition of the work of RediCare over the last 5 years.
'RediCare Control has shown consistent clinical outcomes in variety of settings, including corporate, primary care and direct to consumer environments across a variety of participants.’ commented Dr. Niall Colwell Consultant Cardiologist.
RediCare is a digital therapeutics firm. With our core product RediCare ControlDTx patients are transforming their health across the spectrum of metabolic health. They are experiencing clinically significant reductions in Weight, HbA1c, Blood Pressure and improved Lipid profiles and PCOS remission. Many Type 2 Diabetic patients have reduced and eliminated their diabetes medications.
RediCare ControlDTx is creating a new normal in prescription digital therapeutics for treating cardiometabolic diseases. We envision a new way to treat diseases like Type 2 diabetes and heart disease by targeting the root cause, not just the effects, using prescription digital therapeutics to deliver personalized clinically validated lifestyle therapy.
RediCare partners with primary care practices in the UK and Ireland and serves over 140 corporate clients with chronic disease screening and management services.